x

Efficient assessment of drug safety and toxicity can be a complex and time consuming matter. 

Read how we can help

Our services in cardiac safety & toxicity evaluation

Efficient assessment of drug safety and toxicity can be a complex and timely matter. Depending on the compound, cardiac toxicity will be displayed either acutely or after longer exposure. In addition, one should ideally take both structural as well as functional aspects of cardiac toxicity into account. Knowing the potential cardiotoxic effects of drug candidates as early as possible will decrease drug attrition rates and save time and costs in drug development. Access to high quality, standardized and reproducible hiPSC-derived cardiomyocytes can be of great value to achieve this.

Ncardia develops and delivers integrated cardiovascular services to enhance the assessment of cardiac safety and toxicity of drug candidates. Our services are based on fully functional and validated hiPSC-derived cardiomyocytes that are manufactured under strict quality assurance. The assays we provide can also be used for efficacy studies.

Benefits

Benefits of our safety services:

High quality – our safety pharmacology experts perform the studies on validated platforms
Save time - no assay optimization and data analysis needed – let our experts do this for you
Reliable – assays are based on fully functional and validated hiPSC-derived cardiomyocytes
Versatile – we offer a broad range of optimized assays on various platforms
Flexible – we will make sure to meet your specific needs

How we work

What we offer

MEA

Cardio.Acute Service

An acute MEA analysis

Delivers an acute cardiac safety profile of your compounds following the current protocols of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative for microelectrode arrays (MEA) analysis.

CL

Cardio.Long Service

A longer-term MEA and impedance analysis

A (electro)physiological assessment of the potentially longer-term (0-48 hours) toxic effects of your compounds on hiPSC-derived cardiomyocytes as measured by a combination of MEA and impedance.

 

CP

Cardio.Plex Service

A multiplex of MEA, impedance and structural toxicity analysis

A multiparametric approach to deliver an extensive cardiotoxicity profile of your compounds. This service includes an analysis by impedance (contractility), microelectrode array (electrophysiology) and biomarker (e.g. Troponin I) release (structural).

 

CE

Cardio.Effect Service

A longer-term impedance analysis

Delivers a cost-effective, long-term cardiac safety profile based on label-free impedance analysis. Ideal for screening large numbers of compounds.

 

CF

Cardio.Force Service

Industry’s first true contractile force measurement

Provides true force measurement to study the effect of drug candidates on the contractility and force-frequency relationships of hiPSC-derived cardiomyocyte.

CF

Cardio.Flux Service

A calcium-flux analysis

High-throughput screening of acute drug effects on cardiomyocyte electrophysiology by analyzing the intracellular calcium transients.

CT

Cardio.Tox Troponin I Service

A structural toxicity analysis

Delivers a structural cardiotoxicity profile of your compounds based on the release of the cardiac specific biomarker Troponin I by hiPSC-derived cardiomyocytes.

 

CPS

Customized Project Service

Did not find what you were looking for? Or are you interested in a different cell model like endothelial cells, smooth muscle cells or neural cells?

Let us know what your needs are and we will develop a customized safety/toxicity service for you.

 

Questions?

Do you have questions about drug safety and toxicity screening? Our experts are happy to help.